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Strengths and limitations of this study
 ► Adequate fluid therapy is a major determinant of 
outcomes in acute pancreatitis, however, there is no 
consensus on the rate, type and volume of fluids to 
be administered. Goal-directed fluid therapy (GDFT) 
based on stroke volume (SV) optimisation has been 
used after major surgery with a reduction in com-
plications, however, delivering this intervention on 
the ward has been challenging without invasive 
monitoring.
 ► Novel development of non-invasive cardiac output 
monitoring (NICOM) technologies allows GDFT to 
be delivered in the ward based on haemodynamic 
parameters. This trial is the first GDFT randomised 
trial in acute pancreatitis using NICOM in the ward 
setting for SV optimisation.
 ► The golden period for intervention in acute pan-
creatitis is in the early phase of disease to prevent 
progression to severe inflammatory processes and 
complications. A major challenge in this trial is re-
cruitment and delivering the intervention in the ear-
ly hours of unplanned admission which is shared 
across trials in emergency care.
AbStrACt
Introduction Acute pancreatitis is an inflammatory 
disease of the pancreas with high risk of developing 
multiorgan failure and death. There are no effective 
pharmacological interventions used in current clinical 
practice. Maintaining fluid and electrolyte balance is the 
mainstay of supportive management. Goal-directed fluid 
therapy (GDFT) has been shown to decrease morbidity and 
mortality in surgical conditions with systemic inflammatory 
response. There is currently no randomised controlled 
trial (RCT) investigating the role of GDFT based on cardiac 
output parameters in patients with acute pancreatitis 
in the ward setting. A feasibility trial was designed to 
determine patient and clinician support for recruitment 
into an RCT of ward-based GDFT in acute pancreatitis, 
adherence to a GDFT protocol, safety, participant 
withdrawal, and to determine appropriate endpoints for a 
subsequent larger trial to evaluate efficacy.
Methods and analysis The GDFT in Acute Pancreatitis 
trial is a prospective two-centre feasibility RCT. Eligible 
adults admitted with new onset of acute pancreatitis will 
be enrolled and randomised into ward-based GDFT (n=25) 
or standard fluid therapy (n=25) within 6 hours from 
the diagnosis and continuing for the following 48 hours. 
Cardiac output parameters will be monitored with a 
non-invasive device (Cheetah NICOM; Cheetah Medical). 
The intervention group will consist of a protocolised 
GDFT approach consisting of stroke volume optimisation 
with crystalloid fluid boluses, while the control group 
will receive standard care fluid therapy as advised by 
the clinical team. The primary endpoint is feasibility. 
Secondary endpoints will include safety of the intervention, 
complications, mortality, admission to intensive care unit, 
cost and quality of life.
Ethics and dissemination Ethics approval was granted 
by the London Central Research Ethics Committee (17/
LO/1235, project ID: 221872). The results of this trial will 
be presented to international conference with interest in 
general surgery and acute care and published in a peer-
reviewed journal.
trial registration number ISRCTN36077283.
IntroduCtIon
Acute pancreatitis is a sudden onset inflam-
matory process of the pancreas, with vari-
able involvement of local or remote organ 
systems. The annual incidence of acute 
pancreatitis in the UK is approximately 30 
per 100 000 of the population.1 This equates 
to approximately 18 000 people developing 
acute pancreatitis every year in the UK.1 
There has been an increase in the incidence 
of pancreatitis in the last two decades.2 Gall-
stones and excessive alcohol are the two 
main causes for acute pancreatitis in the 
UK.3 Increasing age, male gender and lower 
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socioeconomic class are associated with a higher inci-
dence of acute pancreatitis.1
The clinical manifestation of acute pancreatitis is 
believed to be caused by activation of inflammatory path-
ways either directly by the pathologic insult or indirectly 
by activation of trypsin, a protease which can break down 
the pancreas.4 The average 60-day mortality associated 
with acute pancreatitis is 6.4%.1 Deaths occur as a result of 
a massive fluid extravasation from the inflamed pancreas 
combined with a severe systemic inflammatory response 
in the early stage and mainly from local complications 
in the late stage.5 The systemic complications occurring 
in the early phase result in poor oxygen delivery to the 
tissues and include worsening of pre-existing illnesses 
such as heart or chronic lung disease. Local complica-
tions which occur in the later phase include pancreatic 
pseudocysts, infected collections and pancreatic necrosis. 
These early and late complications are the major causes 
of the mortality associated with acute pancreatitis.6 7 They 
are also largely responsible for the decreased health-re-
lated quality of life (HRQoL) and loss of work days 
following acute pancreatitis.8 Thus, acute pancreatitis 
has a major effect on UK society with its complications 
having a significant impact on patients, their next of kin 
and their employers.
Various pharmacological interventions have been 
evaluated in acute pancreatitis, but none are in current 
clinical practice.9 Supportive management in terms of 
maintenance of fluid and electrolyte balance remains the 
mainstay in the treatment of acute pancreatitis. Despite 
the key importance of fluid therapy, a recent systematic 
review has highlighted that there is a lack of information 
on the optimal fluid therapy in acute pancreatitis.9 10 
There has also been a decline in research in treatments 
for acute pancreatitis in general.11
The clinical presentation of acute pancreatitis varies 
from mild to severe life-threatening conditions. There 
is some evidence for aggressive fluid therapy with Hart-
mann’s solution in those with severe disease. However, 
the rate and volume of fluid therapy is still debated for 
those with mild or moderate disease. Hence, high-quality 
randomised controlled trials (RCT) in fluid therapy for 
acute pancreatitis are necessary.
Goal-directed fluid therapy (GDFT) is a complex 
intervention in which intravenous fluid is given to opti-
mise haemodynamic variables. This is achieved by stroke 
volume (SV) optimisation using a cardiac output (CO) 
monitor. RCTs have shown that GDFT decreases compli-
cations and mortality in other situations associated with a 
systemic inflammatory response.12 13 Most of these trials 
however involved cardiac output monitoring for GDFT 
during surgery or in the intensive therapy unit (ITU) 
and not in a ward-based setting. For GDFT to be bene-
ficial in acute pancreatitis, which involves a cascade of 
inflammatory events, therapy is likely to be most bene-
ficial if commenced at the earliest opportunity to inter-
vene following the onset of pancreatitis which would 
equate with the time of admission to hospital. There 
has been one RCT on ward-based GDFT in patients 
with acute pancreatitis comparing the effect of GDFT 
with lactated ringers to normal saline on inflammatory 
response.14 However, the trial was based on optimisation 
of blood urea nitrogen and not cardiac output parame-
ters and failed to show a reduction in the inflammatory 
response or improved clinical outcomes. While other 
endpoints such as heart rate, urine output, haematocrit 
levels and central venous pressures have been suggested 
for fluid therapy in acute pancreatitis, it is the optimisa-
tion of intravascular volume with fluid therapy guided by 
cardiac output measures that has been previously shown 
to be effective in decreasing complications and mortality 
in major surgery.15 16 There is currently no RCT investi-
gating the role of ward-based GDFT using cardiac output 
parameters as target in patients with acute pancreatitis.
With the development of non-invasive cardiac output 
monitors such as Cheetah NICOM (Cheetah Medical, 
Maidenhead, Berkshire, UK), it is possible to measure the 
cardiac output in a ward setting.17 Ward-based GDFT has 
the potential to decrease the early inflammatory response 
and hence complications related to acute pancreatitis 
which might result in decreased mortality and improved 
HRQoL. Reduced inflammation would also lead to a 
reduced intensive care unit (ICU) and hospital stay 
providing significant cost savings to the National Health 
Service (NHS), employers and care providers. This 
two-centre RCT will aim to assess the feasibility of guiding 
the initial 48 hours of intravenous fluid administration in 
patients with acute pancreatitis using ward-based GDFT.
MEthodS
Study design and setting
The GDFT in Acute Pancreatitis (GAP) trial has been 
designed in accordance with the Standard Protocol Items: 
Recommendations for Interventional Trials guidelines as 
a two-centre feasibility RCT.18 The study will primarily 
investigate the ability to recruit patients at the selected 
sites to a feasibility RCT of ward-based GDFT versus stan-
dard fluid therapy in patients with acute pancreatitis, the 
rate of withdrawal from GDFT protocol and the reasons 
for withdrawal from GDFT protocol. We will also assess 
the safety and practicality of ward-based GDFT and collect 
outcome measures which can be evaluated as endpoints 
for a subsequent multicentre study on efficacy. Indicative 
costs will be collected to inform a subsequent cost-effec-
tiveness study. The trial outline is illustrated in figure 1 
and the schedule of enrolment, interventions and assess-
ments is shown in table 1.
Participants
Adults (>16 years) admitted as an emergency with acute 
pancreatitis will be included. Acute pancreatitis must 
be confirmed by the international consensus criteria 
(box 1).19 The exclusion criteria will be patients trans-
ferred for the management of complications of acute 
pancreatitis, requiring immediate admission to the ICU, 
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Figure 1 Trial flow diagram. Patients are screened by the 
medical and surgical team in the emergency department 
for eligibility and referred for consent and registration. The 
trial nurse or surgical team provide trial patient information 
sheets (abbreviated and full versions) and gain informed 
consent. Trial nurses then randomise the patient to either 
GDFT or standard care and commence NICOM monitoring 
for 48 hours. Follow-up will be at the point of discharge, 30 
and 90 days. GDFT, goal-directed fluid therapy; GP, general 
practitioner; HRQoL, health-related quality of life; NICOM, 
non-invasive cardiac output monitoring.
chronic pancreatitis in whom an acute exacerbation 
cannot be confirmed, a history of cardiac failure in the 
past 3 months and those unable to provide fully informed 
consent.
recruitment
Patients referred from the emergency department for 
admission through the emergency surgical team will be 
screened by the general surgical registrar on call. Due to 
the time-dependant nature of this trial, similar to most 
trauma and emergency surgery studies, a summarised and 
abbreviated patient information sheet will be provided for 
patients initially on arrival and they will be subsequently 
provided with an in-depth version. Informed consent will 
be obtained by a member of the clinical or research team 
trained in Good Clinical Practice.20 The trial nursing 
staff responsible for instituting the trial intervention will 
be contacted within 4 hours of diagnosis. Intervention 
or standard of care will commence within 6 hours of the 
diagnosis for the next 48 hours of inpatient stay. Since 
the primary goal of this study is to assess the feasibility of 
delivering ward-based GDFT, patients requiring escalation 
of care and admission to ICU during the intervention 
will only have continued cardiac output monitoring until 
completion of the 48 hours’ period.
randomisation
This will be performed using ‘Sealed Envelope’, an inter-
net-based randomisation system ( www. sealedenvolpe. 
com). Eligible patients who have consented to take part 
in the trial will be 1:1 randomised to ward-based GDFT 
or standard care, stratified by site on admission, prior 
to ward transfer. The trial research nurse responsible 
(unblinded) will log into the database and create rando-
misation codes for both groups online. Information on 
randomisation will be stored in the case report form 
(CRF).
Intervention
GDFT will be carried out for 48 hours. It can take up to 
48 hours for the severity of pancreatitis to manifest and 
is considered the ‘golden’ period for interventions that 
may decrease severity.21 GDFT will be based on a standard 
algorithm which uses the SV derived from non-invasive 
cardiac output monitoring (NICOM) using the Cheetah 
NICOM (figure 2). The fluid administration regimen will 
be as follows: maintenance fluid should be administered 
at 1.5 mL/kg/hour (based on ideal body weight) using a 
balanced crystalloid solution to be ensured that a regu-
lated volume of fluid was given per hour in order to avoid 
fluid overload in this group. Previous studies have been 
criticised for excessive maintenance fluid prescribed in 
the GDFT group.22 It was also felt that placing restrictions 
on the maintenance fluid prescription may influence 
decision-making in this group and affect the enthusiasm 
for clinicians to agree in patients participating in the 
study.
On admission SV is recorded and an initial bolus of 
250 mL of intravenous fluid (balanced electrolyte solu-
tion) is given over 5–10 min. If there is a sustained rise in 
SV of greater than 10% for 15 min or more, this indicates 
fluid responsiveness and a repeat 250 mL bolus will be 
given. If there is not a rise in SV of greater than 10% then 
the patient is deemed fluid unresponsive and no further 
fluid boluses are administered. SV monitoring continues 
four hourly and if it decreases by more than 10% a further 
fluid bolus is administered as above.
Control (standard care group)
The choice of fluid type, volume and rate of admin-
istration on the first 48 hours of admission for patients 
randomised to the control arm will be decided by the 
clinical team caring for the patient in order to mimic a 
real-world situation. Cardiac output monitoring variables 
will be measured every 4 hours on the standard care arm 
during the first 48 hours, however, the results will be 
blinded to the clinical team. The choice of fluid type, 
volume and rate will be recorded in detail. All other clin-
ical, biochemical and HRQoL outcome measures will also 
be recorded for standard of care patients as outlined in 
the ‘outcome measures’ section.
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box 1 International consensus criteria for acute 
pancreatitis
Acute pancreatitis diagnosis confirmed with two of the 
following three features:
 ► Abdominal pain consistent with acute pancreatitis (acute onset of a 
persistent, severe, epigastric pain often radiating to the back).
 ► Serum amylase or lipase activity at least three times greater than 
the upper limit of normal.
 ► Characteristic findings of acute pancreatitis on contrast-en-
hanced CT (CECT) and less commonly MRI or transabdominal 
ultrasonography.
Figure 2 Goal-directed fluid therapy (intervention) protocol. 
Flow diagram of SV optimisation with maintenance fluid 
administration. Patients randomised to goal-directed fluid 
therapy (GDFT) will receive a 1.5 mL/kg/hour of intravenous 
crystalloid maintenance fluid and four hourly visits from 
the trial nurses. At the first 4-hour visit, a bolus of 250 mL 
crystalloid over 5–10 min will be administered. An SV rise of 
>10% would indicate fluid responsiveness and a further cycle 
of fluid bolus is administered until there is no SV rise >10%. 
At the next four hourly visits if SV has dropped by >10% the 
cycle is repeated. SV, stroke volume.
The Cheetah NICOM device (Cheetah Medical) is a 
CE (Conformité Européene) marked device which has been 
purchased for this study and training has been arranged 
for all staff on the equipment and the associated fluid 
administration algorithm which will be a key component 
of the trial. The research team will follow hospital policy 
on signals for ICU outreach reviews and escalation of care 
to ICU. NICOM monitoring and outcome measures will 
be recorded in ICU for both control and GDFT arms.
blinding
It will not be possible to blind the research or clinical 
team during the first 48 hours of the study. However, the 
participants, outcome assessors of HRQoL and statisti-
cians will be blinded to the groups. Patient blinding will 
be aided by NICOM monitoring of both intervention and 
control groups but performing GDFT in the intervention 
group alone. NICOM data from the control group will 
be collected at the same time points as the intervention 
group and will not be available to the treating clinicians.
outcome measures
The primary outcome of the trial will be an assessment of 
feasibility. In particular, the ability to identify and recruit 
patients at the selected sites to a study of acute pancre-
atitis. A recruitment rate of at least 30% over 17-month 
trial period will be deemed as successful. We will also assess 
the availability of study team for a condition presenting 
as an emergency, ability to randomise and commence 
ward GDFT within 6 hours of admission, completion 
rate of 48 hours of GDFT, rate of withdrawal (less than 
20%) from GDFT protocol, reasons for withdrawal from 
GDFT protocol and proportion of complications in the 
two groups. Although the study is not powered to show 
differences in haemodynamic variables, we will analyse 
the haemodynamic data (such as SV and CO) at the end 
of the trial for patients in both groups to, at least, be able 
to conclude that we have optimised SV status of patients 
correctly according to the GDFT protocol drawn at the 
start of the trial. These data will be presented along with 
the main feasibility endpoints.
Several secondary clinical, surgical, biochemical, 
safety and quality of life outcomes will also be collected. 
Mortality will be assessed as well. Clinical outcomes will 
include severity of pancreatitis as assessed by Glasgow 
score, proportion of patients with severe acute pancre-
atitis, necrotising pancreatitis, infected pancreatic 
necrosis, requiring ITU stay, requiring renal replacement 
therapy, requiring ventilation, requiring surgical inter-
ventions for complications related to pancreatitis and 
incidence of positive blood cultures. Resource use data 
for health economic analysis on length of hospital stay, 
length of ICU stay, and number of days ventilated, time to 
return to pre-pancreatitis activities, number of workdays 
lost (in those who work) and costs (NHS and personal 
social services perspectives) will be collected. HRQoL will 
be assessed using the well-validated EuroQol-5 Dimen-
sion (EQ-5D) questionnaire on admission as baseline 
and subsequently on days 7, 30 and 90. All complica-
tions of pancreatitis including treatment-related adverse 
events (postradiological and surgical complications as 
classified by Clavien-Dindo Classification) and serious 
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box 2 baseline characteristics of patients
The intervention group and the control group should have the following 
baseline characteristics:
 ► Age.
 ► Sex.
 ► Ethnicity.
 ► Body mass index (BMI).
 ► Time since onset of symptoms.
 ► Presumed cause of pancreatitis.
 ► Comorbidities.
 ► Baseline observations.
 ► Baseline renal function.
 ► Baseline blood gas parameters.
 ► Glasgow severity score on admission.
 ► Intravenous fluids prior to intervention.
adverse events related to intervention will be recorded 
up to discharge and at follow-up. Routine biochemical 
tests performed as part of clinical care including blood 
gases, liver function tests, clotting profile, renal function, 
amylase, full blood count and C-reactive protein (CRP) 
will be recorded on admission and daily up to 2 weeks and 
biweekly up to discharge. In addition, serum samples will 
be collected from participants in both groups on admis-
sion, 12, 24 and 48 hours’ time points and stored at −80° 
for future analysis of biomarkers in acute pancreatitis.
Follow-up
Participants will be followed for 90 days. All clinical and 
HRQoL outcomes will be measured up to discharge and 
specifically at 30 and 90 days by face-to-face or telephone 
follow-up. CRP will be measured at 24 and 48 hours and 
every 24 hours during the hospital stay as per routine 
clinical practice. Clinical outcomes on follow-up include 
cumulative hospital and ICU stay including readmissions, 
predefined complications including organ failure, severe 
pancreatitis, infected pancreatic necrosis, surgical inter-
ventions, development of sepsis, pulmonary oedema or 
acute respiratory distress syndrome as well as mortality. 
Resource use data include medications, planned and 
unplanned tests and procedures and use of allied health-
care professionals (eg, physiotherapy, occupational 
therapy). HRQoL will be assessed using a validated ques-
tionnaire (EQ-5D).
Sample size calculation
Formal sample size calculations are not appropriate for 
a feasibility study, hence a convenient sample size of 
50 patients, randomised equally to the two groups, has 
been chosen. Sample sizes between 24 and 50 have been 
recommended to estimate the SD required for a sample 
size calculation for a subsequent large RCT aimed at eval-
uating the cost-effectiveness of GDFT.23
Patient and public involvement
Patients involved in the trial preparation were surprised 
that there had been no progress in effective treatment 
for acute pancreatitis and felt that new therapeutic 
approaches were required. Some had experienced late 
complications and felt that better early treatment may 
prevent these late complications. The trial protocol was 
presented and discussed with patients to ensure that 
patient-centred outcomes such as survival and quality of 
life were appropriately measured, and advice was sought 
on the conduct of the study. The burden of the inter-
vention was assessed by patient representatives and was 
thought to be ethical and appropriate. The outcomes of 
the study will be disseminated to the participants after 
review and formulation by our study patient represen-
tative. We wish to thank our patient representatives for 
their contribution and participation in this process.
trial management structure
A Trial Management Group (TMG) chaired by the chief 
investigator and comprising leads at different sites, 
ICU research nurses, the surgical team representative, 
research fellows, statistician, qualitative researchers and 
health economist will meet fortnightly to discuss trial 
progress and address issues in recruitment and delivering 
the intervention. Trial progress will be reported to inde-
pendent data monitoring committee (DMC) comprising 
experts in acute pancreatitis, medical statistics and clin-
ical trials every 6 months.
All serious complications and any mortalities will be 
immediately referred to the sponsor and reported to the 
TMG and independent DMC. The trial will be stopped 
in case of two or more treatment-related suspected unex-
pected serious adverse reactions.
data collection and analysis
Recruitment data which include number of eligible 
patients presenting to the emergency department, number 
of patients screened, number of patients consenting and 
number of patients randomised are recorded in a recruit-
ment log in the emergency department. A Consolidated 
Standards of Reporting Trials diagram will be presented 
to provide a detailed description of participant numbers 
at each time point during the trial.24 A paper CRF is 
created for each participant enrolled into the study. The 
data collected on the paper CRF are then transferred to 
a secure online database using the Research Electronic 
Data Capture platform.
Since this is a feasibility study, all analyses other than 
recruitment rate and withdrawal rates should be consid-
ered exploratory. The two groups will be compared to 
ensure they have similar baseline characteristics (box 2) 
using means and SDs or medians and IQRs for contin-
uous variables, as appropriate, and frequency counts and 
percentages for categorical variables.
For the primary outcome, that is, feasibility, the propor-
tion of patients who consent to be randomised and the 
rate of withdrawal from GDFT protocol will be presented 
with a 95% CI. The median number of complications, 
graded by the Clavien-Dindo Classification, in each 
group will be presented. The proportions of people with 
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complications between the two groups will be presented 
and compared using appropriate statistical test and 95% 
CI.
For the secondary outcomes, among patients who 
participate in the trial, all clinical and surgical outcome 
measures will be presented for each group separately 
using the mean, SD, median, minimum and maximum 
for continuous outcomes and using frequencies and 
proportions for categorical variables.
Quality of life will also be summarised for each group 
using mean profile plots over time. The mean difference 
in quality of life scores between the two groups at 7 days 
up will be presented with a 95% CI.
Kaplan-Meier survival estimates and plots will be 
presented to compare survival rates between the two 
groups.
All other secondary outcomes collected over time 
will be summarised for each group using mean profile 
plots. Mean differences for continuous outcomes and 
difference in proportion for binary outcomes shall be 
presented, with appropriate 95% CIs, at 30 and 90 days.
The number and nature of adverse events shall be 
reported for each group. No formal comparisons between 
the groups will be made and no hypothesis tests will be 
carried out. The results will inform us how sensitive the 
outcome measures are and, along with other informa-
tion, will be used to determine the primary outcome of 
a subsequent large RCT. The results will also inform a 
sample size calculation for the primary outcome chosen.
Assessment of feasibility
This is a feasibility study and one aspect of this feasi-
bility evaluation is the ability to recruit patients with 
acute pancreatitis into a trial of this nature. According 
to hospital episode statistics, an in-house review of admis-
sions for acute pancreatitis to the Royal Free Hospital 
over the last 3 years showed 107 cases per year. After 
excluding patients who were transferred from another 
hospital for tertiary care, those who required immediate 
ICU admission, those with chronic pancreatitis in whom 
an acute exacerbation could not be confirmed by internal 
consensus criteria, current or past cardiac failure, or 
unable to provide fully informed consent, 80 patients per 
year would be eligible for this trial from a single centre. 
With a second centre we would anticipate 120 suitable 
patients per year. We anticipate recruiting at least 30% 
of potential participants which equates to 36 participants 
annually and a recruitment time of 17 months to recruit 
the 50 patients.
For feasibility assessment, a recruitment log will be 
used to collect information on suitability and consent 
rate as well as availability of trials team for GDFT, consent, 
failure to commence ward GDFT, withdrawal with reasons 
and failure to complete the study. In case of lower than 
anticipated recruitment at 6 months, we will perform 
the following: (A) analyse the results of the qualitative 
research earlier and identify the reasons for poor recruit-
ment (and take actions to resolve the problems) if we 
get the anticipated number of patients screened but the 
recruitment rate is lower than anticipated; (B) recruit-
ment of additional centres if we do not get the antici-
pated number of potential participants screened but the 
recruitment rate is at least as good as the anticipated rate; 
(C) a combination of the above if the number of poten-
tial participants screened and the recruitment rate are 
lower than anticipated.
We will explore the reasons for participation and non-par-
ticipation of eligible patients, and patients and clinicians’ 
acceptability of the trial to assist in optimisation of recruit-
ment strategies employed for the definitive trial. Non-partic-
ipation can be related to how the clinical trial is presented 
to the patient, and how the patient assimilates this informa-
tion. It is therefore important to understand how patients 
perceive information about potential participation and 
their experiences of receiving information relating to the 
trial. Interviews with a sample of eligible patients will explore 
patient perspectives of treatment, their understanding of 
the two treatments, reasons for taking part or refusing the 
trial and the acceptability of randomisation between the 
procedures. Interviews with clinical staff will explore their 
views about the trial, clinical equipoise and their under-
standing of the recruitment challenges. Semistructured 
interviews will be informed by a topic guide developed in 
conjunction with the TMG which includes patient repre-
sentatives. Patient information sessions (recruiter meet-
ings) will be audio recorded to examine how information 
is presented, and identify issues potentially affecting trial 
recruitment. Patient information sessions will be analysed 
at an early stage if there is poor recruitment and will inform 
the development of any additional training materials for 
recruitment for the definitive trial.
Progress to full trial
The criteria to progress to a subsequent full trial will be 
determined quantitatively as (A) consent rate of at least 
30%, the ability to recruit 50 patients to the study at the 
two sites over 17 months, (B) GDFT can be successfully 
performed within 6 hours of diagnosis of acute pancreatitis 
and can be continued until at least 48 hours after admis-
sion in a minimum of 80% of participants randomised 
to GDFT, and (C) the complication rate in the interven-
tion group is not more than 10% higher than that of the 
control group at 90 days. A cut-off of 30% has been chosen 
for recruitment as this would be an achievable target in 
the definitive trial. A lower recruitment rate may indicate 
a lack of acceptability among clinicians and/or patients 
to participate in the definitive trial. In addition, a recruit-
ment rate less than 30% is likely to make the subsequent 
definitive trial very expensive. A less than 30% recruitment 
may also highlight issues related to generalisability of the 
results, indicating a reduction in value of the subsequent 
definitive trial in terms of applicability in NHS.
dISCuSSIon
Acute pancreatitis is an inflammatory disease associated 
with a high mortality rate.25 Adequate fluid resuscitation 
8 Froghi F, et al. BMJ Open 2019;9:e028783. doi:10.1136/bmjopen-2018-028783
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has been identified as a key intervention in prevention of 
systemic complications, however, the debate over the type, 
rate or amount of intravenous fluids to be administered is 
ongoing.26 With the advent of NICOM devices, delivering 
haemodynamic-guided fluid replacement is now possible 
in patients admitted to the general ward. The GAP trial 
is the first ward-based RCT of GDFT in acute pancreatitis. 
The trial will assess feasibility and safety of delivering this 
intervention in the ward and if successful, will progress to 
a multicentre trial to assess efficacy and cost-effectiveness.
trIAl StAtuS
The GAP trial opened for recruitment on 8 January 2018 
for a period of 18 months.
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